Atlas Trials

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Clinical trial NCT04519476 · UNKNOWN

Trial details

NCT number
NCT04519476
Sponsor
Oncotherapeutics
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Refractory Multiple Myeloma
Start date
2020-11-01
Primary completion
2023-12-29
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.